Display options
Cite
Joshi S, Chaudhari AA, Dennis V, et al. Anti-RSV Peptide-Loaded Liposomes for the Inhibition of Respiratory Syncytial Virus. Bioengineering (Basel). 2018;5(2)doi: 10.3390/bioengineering5020037.
Joshi, S., Chaudhari, A. A., Dennis, V., Kirby, D. J., Perrie, Y., & Singh, S. R. (2018). Anti-RSV Peptide-Loaded Liposomes for the Inhibition of Respiratory Syncytial Virus. Bioengineering (Basel, Switzerland), 5(2), . https://doi.org/10.3390/bioengineering5020037
Joshi, Sameer, et al. "Anti-RSV Peptide-Loaded Liposomes for the Inhibition of Respiratory Syncytial Virus." Bioengineering (Basel, Switzerland) vol. 5,2 (2018). doi: https://doi.org/10.3390/bioengineering5020037
Joshi S, Chaudhari AA, Dennis V, Kirby DJ, Perrie Y, Singh SR. Anti-RSV Peptide-Loaded Liposomes for the Inhibition of Respiratory Syncytial Virus. Bioengineering (Basel). 2018 May 09;5(2). doi: 10.3390/bioengineering5020037. PMID: 29747393; PMCID: PMC6027156.
Copy Download .nbib Format: NLM
Share it on

Bioengineering (Basel). 2018 May 09;5(2). doi: 10.3390/bioengineering5020037.

Anti-RSV Peptide-Loaded Liposomes for the Inhibition of Respiratory Syncytial Virus.

Bioengineering (Basel, Switzerland)

Sameer Joshi, Atul A Chaudhari, Vida Dennis, Daniel J Kirby, Yvonne Perrie, Shree Ram Singh

Affiliations

  1. Center for NanoBiotechnology Research, Alabama State University, Montgomery, AL 36016, USA. [email protected].
  2. Center for NanoBiotechnology Research, Alabama State University, Montgomery, AL 36016, USA. [email protected].
  3. Center for NanoBiotechnology Research, Alabama State University, Montgomery, AL 36016, USA. [email protected].
  4. Aston Pharmacy School, Life and Health Sciences, Aston University, Birmingham B4 7ET, UK. [email protected].
  5. Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow G4 0RE, UK. [email protected].
  6. Center for NanoBiotechnology Research, Alabama State University, Montgomery, AL 36016, USA. [email protected].

PMID: 29747393 PMCID: PMC6027156 DOI: 10.3390/bioengineering5020037

Abstract

Although respiratory syncytial virus (RSV) is one of the leading causes of acute respiratory tract infection in infants and adults, effective treatment options remain limited. To circumvent this issue, there is a novel approach, namely, the development of multifunctional liposomes for the delivery of anti RSV-peptides. While most of the peptides that are used for loading with the particulate delivery systems are the penetrating peptides, an alternative approach is the development of liposome-peptide systems, which are loaded with an RSV fusion peptide (RF-482), which has been designed to inhibit the RSV fusion and block infection. The results of this work have revealed that the liposomes themselves can serve as potential RSV inhibitors, whilst the anti-RSV-peptide with liposomes can significantly increase the RSV inhibition when compared with the anti-RSV peptide alone.

Keywords: hydrophilic; liposomes; peptide; respiratory syncytial virus

References

  1. Vaccine. 2000 Jan 6;18(11-12):1110-7 - PubMed
  2. J Virol. 1992 Feb;66(2):1277-81 - PubMed
  3. Int J Nanomedicine. 2013;8:1403-15 - PubMed
  4. Nature. 1974 Nov 15;252(5480):252 - PubMed
  5. J Virol. 2001 Aug;75(15):6825-34 - PubMed
  6. Int J Pharm. 2016 Nov 30;514(1):160-168 - PubMed
  7. Hum Vaccin Immunother. 2013 Jun;9(6):1374-81 - PubMed
  8. Antimicrob Agents Chemother. 2015 Nov;59(11):7109-12 - PubMed
  9. PLoS One. 2012;7(5):e36812 - PubMed
  10. J Clin Virol. 2014 Sep;61(1):138-44 - PubMed
  11. Mol Pharm. 2014 Dec 1;11(12):4374-84 - PubMed
  12. Antiviral Res. 1998 Aug;39(2):63-79 - PubMed
  13. Pediatr Rev. 2014 Dec;35(12):519-30 - PubMed
  14. Ther Adv Vaccines. 2014 Nov;2(6):159-82 - PubMed
  15. Proc Natl Acad Sci U S A. 2010 Jan 5;107(1):320-5 - PubMed
  16. J Immunol Methods. 2017 Jul;446:15-20 - PubMed
  17. J Infect Dis. 2015 Mar 15;211 Suppl 1:S1-S20 - PubMed
  18. J Infect Dis. 1988 Jan;157(1):143-8 - PubMed
  19. Int J Pharm. 2008 Dec 8;364(2):272-80 - PubMed
  20. Eur J Biochem. 1972 Jan 21;24(3):485-91 - PubMed
  21. Biochem J. 1972 Aug;129(1):123-33 - PubMed
  22. Antimicrob Agents Chemother. 2000 Mar;44(3):688-92 - PubMed
  23. Ann N Y Acad Sci. 1978;308:275-80 - PubMed
  24. J Med Microbiol. 2003 Oct;52(Pt 10):893-6 - PubMed
  25. Nat Chem Biol. 2016 Feb;12(2):87-93 - PubMed
  26. J Virol. 2014 Oct;88(20):11899-914 - PubMed
  27. Clin Microbiol Rev. 2010 Jan;23(1):74-98 - PubMed
  28. Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14172-7 - PubMed
  29. Adv Virol. 2013;2013:595768 - PubMed
  30. J Vis Exp. 2014 Nov 04;(93):e52065 - PubMed
  31. N Engl J Med. 2005 Apr 28;352(17):1749-59 - PubMed
  32. Virology. 1994 May 1;200(2):801-5 - PubMed
  33. Biomaterials. 2014 Nov;35(35):9484-94 - PubMed
  34. Clin Rev Allergy Immunol. 2013 Dec;45(3):331-79 - PubMed
  35. Vaccine. 2001 Apr 30;19(23-24):3301-10 - PubMed
  36. J Lipid Res. 2015 Mar;56(3):578-87 - PubMed
  37. J Mol Biol. 1965 Aug;13(1):238-52 - PubMed
  38. Nat Rev Immunol. 2011 Nov 04;11(12):865-72 - PubMed
  39. FEBS Lett. 1971 Apr;14(2):95-99 - PubMed
  40. Antiviral Res. 2015 Apr;116:34-44 - PubMed
  41. Antimicrob Agents Chemother. 2015 Dec 14;60(3):1264-73 - PubMed
  42. J Virol. 2012 Oct;86(19):10880-4 - PubMed
  43. Org Biomol Chem. 2014 Feb 28;12(8):1237-44 - PubMed

Publication Types